Disclosure: This post was part of the Break Up with Your Makeup program sponsored by Galderma Laboratories, L.P. through their partnership with POPSUGAR. While I was compensated by POPSUGAR to write a post about Galderma Laboratories, L.P, all opinions are my own. You should discuss any medications with your doctor.
My complexion is far from perfect. Like many women, I struggle with imperfect skin. But masking these imperfections with foundations and concealers can lead to a vicious cycle. Yes, heavy face makeup camouflages your problem areas, but they can exacerbate skin issues, leaving you more dependent on these products.
For many of the 16 million Americans living with the chronic, inflammatory skin disorder called rosacea, makeup has become a crutch rather than a fun accessory. In fact, if you’ve been covering up your facial redness instead of treating it, you are not alone—many rosacea sufferers use cosmetics to cover up redness.
It’s time to break the cycle. Stop concealing and start healing. Mirvaso® (brimonidine) Topical Gel, 0.33%* is one of Galderma’s prescription products, and is the first and only prescription treatment specifically developed and indicated to treat the persistent facial redness of rosacea. Apply Mirvaso Gel to your face once daily and it may start working in as little as 30 minutes. Mirvaso Gel won’t just cover up redness, it may reduce redness for up to 12 hours!
Galderma Laboratories, L.P., the brand behind Mirvaso Gel, is hosting a contest to raise awareness of the condition and to encourage those who suffer from rosacea to “Break Up with Your Makeup.” Submit a no-makeup selfie along with a 100-word story about your experience with rosacea for a chance to win a trip to NYC for the NY Film Festival.
Important Safety Information
Indication: Mirvaso® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
*Each gram of gel contains 5mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://WWW.FDA.GOV/MEDWATCH or call 1-800-FDA-1088.
All trademarks are the property of their respective owners.